Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.
Therapeutic applications of iPSCs have surged in recent years. 2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB), it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration. In another world-first, Cynata Therapeutics received approval in 2016 to launch the world's first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its “off-the-shelf” iPSC-derived CAR-T cell product candidate. Numerous physician-led studies using iPSCs are also underway in Japan, a leading country for basic and applied iPSC applications.
iPS Cell Market Competitors
Today, FUJIFILM CDI has emerged as one of the largest commercial players within the iPSC sector. FUJIFILM CDI was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time ever. The feat was accomplished simultaneously by Dr. Shinya Yamanaka's lab in Japan.
In 2009, ReproCELL, a company established as a venture company originating from the University of Tokyo and Kyoto University, made iPSC products commercially available for the first time with the launch of its human iPSC-derived cardiomyocytes, which it called ReproCario.
A European leader within the iPSC market is Ncardia, formed through the merger of Axiogenesis and Pluriomics. Founded in 2001, Axiogenesis initially focused on generating mouse embryonic stem cell-derived cells and assays, but after Yamanaka's iPSC technology became available, it became the first European company to license it in 2010. Ncardia's focus is on preclinical drug discovery and drug safety through the development of functional assays using human neuronal and cardiac cells.
In total, at least 68 distinct market competitors now offer various types of iPSC products, services, technologies and therapies.
iPS Cell Commercialization
Methods of commercializing induced pluripotent stem cells (iPSCs) are diverse and continue to expand. iPSC cell applications include, but are not limited to:
- Research Products: Market competitors provide iPSC specific tools to scientists worldwide, including human iPSC lines and differentiated cell types, as well as optimized reagents, protocols, differentiation kits, and more.
- Drug Development & Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.
- Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
- Toxicology Screening: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.
- Personalized Medicine: The use of techniques such as CRISPR enables precise, directed the creation of knock-outs and knock-ins (including single-base changes) in many cell types. Pairing iPSCs with genome editing technologies has added a new dimension to personalized medicine.
- Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models “in a dish.”
- Stem Cell Banking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors.
- Other Applications: Other applications for iPSCs include areas like tissue engineering, 3D bioprinting, clean meat production, wildlife conservation, and more.
Since the discovery of iPSC technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics.
Importantly, the report presents a comprehensive market size breakdown for iPSCs by Application, Technology, Cell Type and Geography (North America, Europe, Asia/Pacific, and RoW). It also presents total market size figures and growth rates through 2026.
In addition to the primary and secondary research required for this report, interviews were conducted with notable iPSC industry leaders, including:
- Kaz Hirao, President and COO of FUJIFILM CDI
- Dr. Ross Macdonald, CEO of Cynata Therapeutics
- Robin Smith, CEO of ORIG3N
- Dr. Paul Wotton, Board Member of Cynata Therapeutics
Claim this global strategic report to become immediately informed about the iPSC market, without sacrificing weeks of unnecessary research or being at risk of missing critical market opportunities.
1. Report Overview
1.1 Statement of the Report
1.2 Executive Summary
2.1 Discovery of iPSCs
2.2 Barriers in iPSC Application
2.3 Timeline and Cost of iPSC Development
2.4 Current Status of iPSCs Industry
2.4.1 The Share of iPSC-based Research in the Overall Stem Cell Industry
2.4.2 Major Focuses on iPSC Companies
2.4.3 Commercially Available iPSC-Derived Cell Types
2.4.4 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays
2.4.5 Toxicology/Safety Testing Assays using iPSC-Derived Cell Types
2.5 Currently Available iPSC Technologies
2.6 Advantages and Limitations of iPSCs Technology
3. History of Induced Pluripotent Stem Cells (IPSCS)
3.1 First iPSC generation from Mouse Fibroblasts, 2006
3.2 First Human iPSC Generation, 2007
3.3 Creation of CiRA, 2010
3.4 First High-Throughput screening using iPSCs, 2012
3.5 First iPSCs Clinical Trial Approved in Japan, 2013
3.6 The First iPSC-RPE Cell Sheet Transplantation for AMD, 2014
3.7 EBiSC Founded, 2014
3.8 First Clinical Trial using Allogeneic iPSCs for AMD, 2017
3.9 Clinical Trials for Parkinson’s disease using Allogeneic iPSCs, 2018
3.10 Commercial iPSC Plant SMaRT Established, 2018
3.11 First iPSC Therapy Center in Japan, 2019
4. Research Publications on IPSCS
4.1 Categories of Research Publications
4.2 Percent Share of Published Articles by Disease Type
4.3 Number of Articles by Country
5. IPSCS: Patent Landscape
5.1 Timeline and Status of Patents
5.2 Patent Filing Destinations
5.2.1 Patent Applicant’s Origin
5.2.2 Top Ten Global Patent Applicants
5.2.3 Collaborating Applicants of Patents
5.3 Patent Application Trends iPSC Preparation Technologies
5.4 Patent Application Trends in iPSC Differentiation Technologies
5.5 Patent Application Trends in Disease-Specific Cell Technologies
6. Clinical Trials Involving IPSCS
6.1 Current Clinical Trials Landscape
6.1.1 Clinical Trials Involving iPSCs by Major Diseases
6.1.2 Clinical Trials Involving iPSCs by Country
7. Funding for IPSC
7.1 Value of NIH Funding for iPSCs
7.1.1 NHI’s Intended Funding Through its Component Organizations in 2020
7.1.2 NIH Funding for Select Universities for iPSC Studies
7.2 CIRM Funding for iPSCs
8. Generation of Induced Pluripotent Stem Cells: An Overview
8.1 Reprogramming Factors
8.1.1 Pluripotency-Associated Transcription Factors
8.1.2 Different Cell Sources and Different Combinations of Factors
8.1.3 Delivery of Reprogramming Factors
8.1.4 Integrative Delivery Systems
22.214.171.124 Integrative Viral Vectors
126.96.36.199 Integrative Non-Viral Vectors
8.1.5 Non-Integrative Delivery Systems
188.8.131.52 Non-Integrative Viral Vectors
184.108.40.206 Non-Integrative Non-Viral Delivery
8.2 Overview of Four Key Methods of Gene Delivery
8.3 Comparative Effectiveness of Different Vector Types
8.4 Genome Editing Technologies in iPSCs Generation
9. Human IPSC Banking
9.1 Cell Sources for iPSCs Banking
9.2 Reprogramming methods used in iPSC Banking
9.2.1 Factors used in reprogramming by Different Banks
9.3 Workflow in iPSC Banks
9.4 Existing iPSC Banks
9.4.1 California Institute for Regenerative Medicine (CIRM)
220.127.116.11 CIRM iPSC Repository
18.104.22.168 CIRMS’ Key Partnerships for iPSCs Repository
9.4.2 Regenerative Medicine Program (RMP)
22.214.171.124 Research Grade iPSC Lines for Orphan and Rare Diseases from RMP
126.96.36.199 RMP’s Stem Cell Translation Laboratory (SCTL)
9.4.3 Center for iPS Cell Research and Application (CiRA)
188.8.131.52 FiT: Facility for iPS Cell Therapy
9.4.4 European Bank for Induced Pluripotent Stem Cells (EBiPC)
9.4.5 Korean Society for Cell Biology (KSCB)
9.4.6 Human Induced Pluripotent Stem Cell Initiative (HipSci)
9.4.7 RIKEN - BioResource Research Center (BRC)
9.4.8 Taiwan Human Disease iPSC Consortium
10. Biomedical Applications of IPSCS
10.1 iPSCs in Basic Research
10.1.1 Understanding Cell Fate Control
10.1.2 Cell Rejuvenation
10.1.3 Studying Pluripotency
10.1.4 Tissue and Organ Development and Physiology
10.1.5 Generation of Human Gametes from iPSCs
10.1.6 Providers of iPSC-Related Services for Researchers
10.2 iPSCs in Drug Discovery
10.2.1 Drug Discovery for Cardiovascular Disease using iPSCs
10.2.2 Drug Discovery for Neurological and Neuropsychiatric Diseases
10.2.3 Drug Discovery for Rare Diseases using iPSCs
10.3 iPSCs in Toxicology Studies
10.3.1 Relative Use of iPSC-Derived Cell Types in Toxicity Testing
10.4 iPSCs in Disease Modeling
10.4.1 Cardiovascular Diseases Modeled with iPSCs
10.4.2 Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling
10.4.3 Proportion of iPSC Sources in Cardiac Studies
10.4.4 Proportion of Vector Types used in Reprogramming
10.4.5 Proportion of Differentiated Cardiomyocytes used in Disease Modeling
10.4.6 iPSC-Derived Organoids for Modeling Development and Disease
10.4.7 Modeling Liver Diseases using iPSC-derived Hepatocytes
10.4.8 iPSCs in Neurodegenerative Disease Modeling
10.4.9 Cancer-Derived iPSCs
10.5 iPSCs in Cell-Based Therapies
10.5.1 Ongoing Clinical Trials using iPSCs in Cell Therapy
10.5.1.1 Clinical Trials for AMD
10.5.1.2 Autologous iPSC-RPE for AMD
10.5.1.3 Allogeneic iPSC-RPE for AMD
10.5.1.4 iPSC-Derived Dopaminergic Neurons for Parkinson’s disease
10.5.1.5 iPSC-Derived NK Cells for Solid Cancers
10.5.1.6 iPSC-derived Cells for GvHD
10.5.1.7 iPSC-derived Cells for Spinal Cord Injury
10.5.1.8 iPSC-derived Cardiomyocytes for Ischemic Cardiomyopathy
10.5.2 Leaders in iPSC-Based Cell Therapies
11. Other Novel Applications of IPSCS
11.1 iPSCs in Tissue Engineering
11.1.1 3D Bioprinting Techniques
11.1.3 3D Bioprinting Strategies
11.1.4 Bioprinting Undifferentiated iPSCs
11.1.5 Bioprinting iPSC-Differentiated Cells
11.2 iPSCs in Animal Conservation
11.2.1 iPSC Lines for the Preservation of Endangered Species of Animals
11.2.2 iPSCs in Wildlife Conservation
11.3 iPSCs and Cultured Meat
11.3.1 Funding Raised by Cultured Meat Companies
11.3.4 Global Market for Cultured Meat
12. Deals in the IPSCS Sector
12.1 $250 million Raised by Century Therapeutics
12.2 BlueRock Therapeutics Launched with $225 Million
12.3 Collaboration between Allogene Therapeutics and Notch Therapeutics
12.4 Acquisition of Semma Therapeutics by Vertex Therapeutics
12.5 Evotec’s Extended Collaboration with BMS
12.6 Licensing Agreement between Allele Biotechnology and Astellas Pharma
12.7 Co-development Agreement between Allele & SCM Lifesciences
12.8 Fate Therapeutics Signs $100 Million Deal with Janssen
12.9 Allele’s Deal with Alpine Biotherapeutics
12.10 Editas and BlueRock’s Development Agreement
13. Market Overview
13.1 Global Market for iPSCs by Geography
13.2 Global Market for iPSCs by Technology
13.3 Global Market for iPSCs by Biomedical Application
13.4 Global Market for iPSCs by Cell Types
13.5 Market Drivers
13.6 Market Restraints
13.6.1 Economic Issues
13.6.2 Genomic Instability
13.6.4 Biobanking of iPSCs
14. Company Profiles
14.1 Addgene, Inc.
14.1.1 Viral Plasmids
14.2 Aleph Farms
14.3 Allele Biotechnology and Pharmaceuticals, Inc.
14.3.1 iPSC Reprogramming and Differentiation
14.4 AMS Biotechnology Europe, Ltd. (AMSBIO)
14.4.3 Corneal Epithelial Cells Cultured in StemFit in Clinical Trials
14.5 ALSTEM, INC.
14.6 Applied Biological Materials, Inc. (ABM)
14.6.1 Gene Expression Vectors and Viruses
14.7 Applied StemCell, Inc.
14.7.1 Services & Products
14.8 American Type Culture Collection (ATCC)
14.9 Applied StemCell (ASC), Inc.
14.10 Aruna Bio, Inc.
14.10.1 Program in Stroke
14.10.2 Exosomes as Therapeurics
14.11 Aspen Neuroscience, Inc.
14.12 Axol Bioscience, Ltd
14.12.1 iPSC-derived Cells
14.12.2 Disease Models
14.12.3 Primary Cells
14.12.4 Media & Reagents
14.13 Beckman Coulter Life Sciences
14.13.1 Cell Counters, Sizers and Media Analyzers
14.14 BD Biosciences
14.15 BioCat GmbH
14.15.1 Products & Services
14.16 BlueRock Therapeutics
14.16.1 CELL + GENE Platform
14.19 Cell Biolabs, Inc.
14.20 CellGenix GmbH
14.21 Cell Signaling Technology
14.22 Cellular Engineering Technologies (CET)
14.22.1 iPS Cell Lines
14.23 Cellular Dynamics International, Inc.
14.24 Censo Biotechnologies, Ltd.
14.24.1 Human iPSC Reprogramming Services
14.24.2 iPSC Gene Editing Services
14.24.3 iPSC Target Validation and Assay Services
14.25 Century Therapeutics, LLC
14.25.1 Allogeneic Immune Cell Therapy
14.27 Corning, Inc.
14.28 Creative Bioarray
14.29 Cynata Therapeutics Ltd.
14.29.1 Cymerus MSCs
14.30 Cytovia Therapeutics
14.30.1 iPSC CAR NK Cells
14.31.1 OptiDIFF iPSC Platform
14.31.3 Patient-Derived Custom Cell Lines
14.31.4 Hepatocytes WT
14.31.5 Hepatocyte A1ATD
14.31.6 Hepatocyte GSD1a
14.31.7 Hepatocyte NAFLD
14.31.8 Hepatocyte FH
14.31.9 Pancreatic WT
14.31.10 Pancreatic MODY3
14.32 Fate Therapeutics, Inc.
14.32.1 iPSC Platform
14.32.2 Collaboration with ONO Pharmaceutical Co., Ltd.
14.32.3 Collaboration with Memorial Sloan-Kettering Cancer Center
14.32.4 Collaboration with University of California, San Diego
14.32.5 Collaboration with Oslo University Hospital
14.33 FUJIFILM Cellular Dynamics, Inc.
14.33.1 iCell Products
14.33.2 MyCell Products
14.33.3 FCDI’s Partners & Providers
14.33.4 Groundbreaking Cellular Therapy Applications
14.33.5 New Paradigm for Drug Discovery
14.33.6 FCDI & Stem Cell Banking
14.34 GeneCopoeia, Inc.
14.34.1 Products & Services
14.35 GenTarget, Inc.
14.36 Heartseed, Inc.
14.38 iPS Portal, Inc.
14.39 iXCells Biotechnologies
14.40 Lonza Group, Ltd.
14.40.1 Nucleofector Technology
14.41 Merck/Sigma Aldrich
14.42 Megakaryon Corporation
14.43 Metrion Biosciences, Ltd.
14.43.1 Cardiac Translational Assays
14.44 Miltenyi Biotec B.V. & Co. KG
14.44.1 Cell Manufacturing Platform
14.45.1 iPSC Solutions for Cell Therapy
14.45.2 Drug Safety and Toxicity Services
14.47 Newcells Biotech
14.47.2 iPSC Reprogramming Services
14.47.3 Assay Products and Services
14.47.4 Assay Development
14.49 Phenocell SAS
14.49.1 Human iPSCs
14.50 Platelet BioGenesis
14.51 Pluricell Biotech
14.51.1 Pluricell’s Projects
14.52 PromoCell GmbH
14.53.1 Single Cell Analysis
14.54 R&D Systems, Inc.
14.56 STEMCELL Technologies
14.57 Stemina Biomarker Discovery
14.57.1 Cardio quickPredict
14.57.2 devTOX quickPredict
14.58 Synthego Corp.
14.58.1 CRISPR-Edited iPSCs
14.59 System Biosciences (SBI)
14.60 Takara Bio
14.60.1 Stem Cell Research Products
14.61 Takeda Pharmaceutical Co., Ltd.
14.61.1 Collaboration between CiRA and Takeda
14.61.2 FUJIFILM’s Collaboration with Takeda
14.62 Tempo Bioscience
14.62.1 Human Cell Models
14.63 Thermo Fisher Scientific, Inc.
14.63.1 Products for Stem Cell Culture
14.63.2 Products for Stem Cell Characterization
14.63.3 Products for Stem Cell Engineering
14.64 TreeFrog Therapeutics
14.64.1 C-Stem Technology
14.65 VistaGen Therapeutics, Inc.
14.65.1 CardioSafe 3D
14.66 Waisman Biomanufacturing
14.66.1 GMP iPSCs
14.67 xCell Science, Inc.
14.67.1 Control Lines
14.68 Yashraj Biotechnology, Ltd.
14.68.1 Products and Services for Drug Discovery
List of Figures
Figure 2.1: The Share of iPSC-related Research Compared with other Stem Cell Types
Figure 2.2: Major Focuses of iPSC Companies
Figure 2.3: Commercially Available iPSC-Derived Cell Types
Figure 2.4: Relative Use of iPSC-Derived Cell Types in Toxicology/Safety Testing Assays
Figure 2.5: Toxicology/Safety Testing Assays using iPSC-Derived Cell Types
Figure 3.1: CiRA’s Budget of ¥6.37 Billion
Figure 4.1: Number of Research Publications on iPSCs in PubMed.gov, 2006-2020
Figure 4.2: Percent Share of Published Articles by Research Themes
Figure 4.3: Percent Share of Published Articles by Disease Type
Figure 4.4: Percent Share of iPSC Research Publications by Country
Figure 5.1: Number of Patents Granted, Being Sought and “Dead”
Figure 5.2: Patent Families by Filing Jurisdiction
Figure 5.3: Patent Families by Applicant Origin
Figure 5.4: Top Ten Global Applicants
Figure 5.5: Top Ten Global Collaborators on PSC/iPSC Patents
Figure 5.6: Share of Patents on iPSC Preparation Technologies by Geography
Figure 5.7: Percent Share of iPSC Preparation Methods in the U.S., Japan and Europe
Figure 5.8: Percent Share of Patents Related to Cell Types Differentiated from iPSCs
Figure 5.9: Percent Share of Patent Applications for Disease-Specific Cell Technologies
Figure 5.10: Percent Share of Patents Representing Different Disorders
Figure 6.1: Number of Clinical Trials Involving iPSCs by Year, 2006-2020
Figure 6.2: Clinical Trials Involving iPSCs by Major Diseases
Figure 6.3: Clinical Trials Involving iPSCs by Country
Figure 7.1: Number of NIH Funding for iPSC Projects, 2010-2020
Figure 7.2: Value of NIH Funding for iPSCs by Year, 2010-2020
Figure 8.1: Overview of iPSC Technology
Figure 8.2: Generation of iPSCs from MEF Cultures through 24 Factors by Yamanaka
Figure 8.3: The Roles of OSKM Factors in the Induction of iPSCs
Figure 8.4: Schematic Representation of Delivery Methods for iPSCs Induction
Figure 8.5: Overview of Four Key Methods of Gene Delivery
Figure 9.1: Workflow in iPSC Banks
Figure 10.1: Biomedical Applications of iPSCs
Figure 10.2: Relative Use of iPSC-Derived Cell Types in Toxicity Testing
Figure 10.3: A Schematic for iPSC-Based Disease Modeling
Figure 10.4: Proportion of iPS Cell Lines Generated by Disease Type
Figure 10.5: Proportion of iPSC Sources in Cardiac Studies
Figure 10.6: Proportion of Vector Types used in Reprogramming
Figure 10.7: The Proportion of Differentiated Cardiomyocyte Types
Figure 10.8: Schematic for iPSC-Based Cell Therapy
Figure 11.1: Schematic Representation of Printing Techniques used for iPSC Bioprinting
Figure 11.2: Schematic Showing the use of iPSCs in Protecting Endangered Species
Figure 11.3: Funding raised by Cultured Meat Companies, 2016-2019
Figure 11.4: Estimated Global Market for Cultured Meat, 2023-2030
Figure 13.1: Estimated Global Market for iPSCs by Geography through 2026
Figure 13.2: Estimated Global Market for iPSCs by Technology through 2026
Figure 13.3: Estimated Global Market for iPSCs by Biomedical Application through 2026
Figure 13.4: Estimated Global Market Share for Differentiated Cell Types, 2020
Figure 14.1: Comparison of Conventional Meat Production and Cultured Meat Production
List of Tables
Table 2.1: Commercially Available iPSC Technologies
Table 2.2: Advantages and Limitations of iPSC Technology
Table 3.1: Timeline of the Most Important Milestones in iPSC Research, 2006-2019
Table 4.1: Number of Research Publications on iPSCs in PubMed.gov, 2006-2020
Table 5.1: Patent Families by Filing Jurisdiction
Table 5.2: Patents Granted and Patents Pending in the Global Patent Landscape
Table 6.1: Clinical Trials involving iPSCs as of March 2020
Table 7.1: NHI’s Intended Funding Through its Component Organizations in 2020
Table 7.2: NIH Funding for Select Universities/Organizations for iPSC Studies
Table 7.3: CIRM Funding for Clinical Trials Involving iPSCs
Table 8.1: The Characterization of iPSCs
Table 8.2: Reprogramming Factors used in the Generation of iPSCs
Table 8.3: Different Cell Sources and Different Combinations of Reprogramming Factors
Table 8.1: Comparative Effectiveness of Different Vector Types
Table 8.2: iPSC Disease Models using Isogenic Control Lines Generated by CRISPR/Cas9
Table 9.1: Cell Sources and Reprogramming Agents used in iPSCs Banks
Table 9.2: Diseased iPSC Lines Available in CIRM Repository
Table 9.3: CIRMS’ iPSC Initiative Awards
Table 9.4: Research Grade iPSCs Available with RMP
Table 9.5: Research Grade iPSC Lines for Orphan and Rare Diseases Available with RMP
Table 9.6: SCTL’s Collaborations
Table 9.7: A Partial List of iPSC Lines Available with EBiPC
Table 9.8: List of Disease-Specific iPSCs Available with RIKEN
Table 9.9: An Overview of iPSC Banks Worldwide
Table 10.1: Providers of iPS Cell Lines and Parts Thereof for Research
Table 10.2: Comparison of hiPSC-Based & Animal-Based Drug Discovery
Table 10.3: Drug Discovery for Cardiovascular Diseases using iPSCs
Table 10.4: Drug Discovery for Neurological and Neuropsychiatric Diseases using iPSCs
Table 10.5: Drug Discovery for Rare Diseases using iPSCs
Table 10.6: Examples of Drug testing in iPSC-Derived Disease Models
Table 10.7: Published Human iPSC Disease Models
Table 10.8: Partial List of Cardiovascular and Related Diseases Modeled with iPSCs
Table 10.9: iPSC-Derived Organoids for Modeling Development and Disease
Table 10.10: Liver Diseases and Therapeutic Interventions Modeled using iPSCs
Table 10.11: Examples of iPSC-Based Neurodegenerative Disease Modeling
Table 10.12: Cancer-Derived iPSCs
Table 10.13: Clinical Trials for the Therapeutic Application of iPSC Derivatives, 2013-2019
Table 10.14: U.S. Clinical Trials Involving iPSCs
Table 11.1: Features of Different Bioprinting Techniques
Table 11.2: Bioprinting of iPSC-Derived Tissues
Table 11.3: Timeline of Achievements Made using iPSCs for Conservation of Animals
Table 11.14: Companies Working on Meat Production based on Cellular Agriculture
Table 13.1: Estimated Global Market for iPSCs by Geography, 2019-2026
Table 13.2: Estimated Global Market for iPSCs by Technology, 2019-2026
Table 13.3: Estimated Global Market for iPSCs by Biomedical Application, 2019-2026
Table 13.4: Estimated Global Market for iPSCs by Differentiated Cell Types, 2019-2026
Table 14.1: iPS Cell Lines from CET
- Addgene, Inc.
- Aleph Farms
- Allele Biotechnology and Pharmaceuticals, Inc.
- ALSTEM, INC.
- American Type Culture Collection (ATCC)
- AMS Biotechnology Europe, Ltd. (AMSBIO)
- Applied Biological Materials, Inc. (ABM)
- Applied StemCell (ASC), Inc.
- Aruna Bio, Inc.
- Aspen Neuroscience, Inc.
- Axol Bioscience, Ltd
- BD Biosciences
- Beckman Coulter Life Sciences
- BioCat GmbH
- BlueRock Therapeutics
- Cell Biolabs, Inc.
- Cell Signaling Technology
- CellGenix GmbH
- Cellular Dynamics International, Inc.
- Cellular Engineering Technologies (CET)
- Censo Biotechnologies, Ltd.
- Century Therapeutics, LLC
- Corning, Inc.
- Creative Bioarray
- Cynata Therapeutics Ltd.
- Cytovia Therapeutics
- Fate Therapeutics, Inc.
- FUJIFILM Cellular Dynamics, Inc.
- GeneCopoeia, Inc.
- GenTarget, Inc.
- Heartseed, Inc.
- iPS Portal, Inc.
- iXCells Biotechnologies
- Lonza Group, Ltd.
- Megakaryon Corporation
- Memorial Sloan-Kettering Cancer Center
- Merck/Sigma Aldrich
- Metrion Biosciences, Ltd.
- Miltenyi Biotec B.V. & Co. KG
- Newcells Biotech
- ONO Pharmaceutical Co., Ltd.
- Oslo University Hospital
- Phenocell SAS
- Platelet BioGenesis
- Pluricell Biotech
- PromoCell GmbH
- R&D Systems, Inc.
- STEMCELL Technologies
- Stemina Biomarker Discovery
- Synthego Corp.
- System Biosciences (SBI)
- Takara Bio
- Takeda Pharmaceutical Co., Ltd.
- Tempo Bioscience
- Thermo Fisher Scientific, Inc.
- TreeFrog Therapeutics
- University of California
- VistaGen Therapeutics, Inc.
- Waisman Biomanufacturing
- xCell Science, Inc.
- Yashraj Biotechnology, Ltd.
The content and statistics contained within the publisher's reports are compiled using a broad range of sources, as described below.
- Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register, Chinese Clinical Trial Registry, Others)
- Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
- Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization, Google Patent Search)
- Grant Funding Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK, Others)
- Product Launch Announcements (Trade Journals, Google News)
- Industry Events (Google News, Google Alerts, Press Releases)
- Company News (SEC Filings, Investor Publications, Historical Performance)
- Social Analytics (Google Adwords, Google Trends, Twitter, Topsy.com, Hashtagify.me, BuzzSumo.com)
- Interviews with Stem Cell Industry Leaders
Research & Analysis Methodologies
The publisher employs the following techniques for deriving its market research:
- Historical Databases: As the first and only market research firm to specialize in the stem cell industry, the publisher has 13+ years of historical data on each segment of the stem cell the industry. This provides an extremely rare and robust database for establishing market size determinations, as well as making future market predictions.
- Prolific Interviews with Industry Leaders: As the global leader in stem cell industry data, the publisher has interviewed hundreds of leaders from across the stem cell industry, including the CEO of FUJIFILM CDI, FUJIFILM Irvine Scientific, Pluristem Therapies, Celularity, and many others.
- Industry Relationships: The research team and its President/Founder, Cade Hildreth, Chair and present at a wide range of stem cell industry events, including Phacilitate's Advanced Therapies Week, World Stem Cell Summit (WSCS), Perinatal Stem Cell Society Congress, AABB's International Cord Blood Symposium (ICBS), and other events hosted within the U.S. and worldwide.
- Global Integrated Feedback: Because the publisher maintains the world's largest stem cell industry news site that is read by nearly a million unique readers per year and the company has large social media audiences (25.7K+ followers on Linked, 21.2K+ followers on Twitter, and 4.3K+ followers on Facebook), the publisher is able to publish content relevant to the industry and receive immediate feedback/input from a global community of readers. In short, the publisher's data is crowd-sourced from market participants worldwide, including those in diverse geographic regions.
- Preliminary Research: In addition to the interviews described above, the publisher conducts market surveys, executes social media polls, and aggregates market data from stem cell industry announcements, press releases, and corporate filings/presentations.
- Secondary Research: The publisher summarizes, collects and synthesizes existing market research that is relevant to the market area of interest.
- Future Projections: Using the resources described above, the publisher is uniquely positioned to make future projections about market size, market growth by segment, market trends, technology evolution, funding activities (financing rounds, M&A, and IPOs), and importantly, market leadership (market share by company).